NAVIDEA BIOPHARMACEUTICALS, INC. Business Finance Contracts & Agreements
118 Contracts & Agreements
- Exchange Agreements (6 contracts)
- Loan Agreements (15)
- Note Agreements (9)
- Purchase Agreements (9)
- Registration Rights Agreements (12)
- Release Agreements (1)
- Security Agreements (5)
- Stock Agreements (25)
- Subordination Agreement (3)
- Subscription Agreements (2)
- Underwriting Agreements (3)
- Warrant Agreements (28)
- Second Amendment to Security Agreement dated as of November 27, 2023 between Navidea Biopharmaceuticals, Inc. and John Kim Scott, Jr (Filed With SEC on December 1, 2023)
- Amended and Restated Secured Term Note dated November 27, 2023 (Filed With SEC on December 1, 2023)
- Secured Convertible Promissory Note dated November 27, 2023 (Filed With SEC on December 1, 2023)
- Loan and Securities Exchange Agreement effective as of November 27, 2023 between Navidea Biopharmaceuticals, Inc. and John K. Scott, Jr (Filed With SEC on December 1, 2023)
- Second Amendment to Asset Purchase Agreement dated as of June 14, 2023 between Cardinal Health 414, LLC and Navidea Biopharmaceuticals, Inc (Filed With SEC on June 16, 2023)
- Stock Exchange Agreement dated as of June 1, 2023 between Navidea Biopharmaceuticals, Inc. and John K. Scott, Jr (Filed With SEC on June 5, 2023)
- Stock Purchase Agreement dated as of May 22, 2023 between Navidea Biopharmaceuticals, Inc. and Irwin Bain (Filed With SEC on May 25, 2023)
- Stock Purchase Agreement dated as of May 22, 2023 between Navidea Biopharmaceuticals, Inc. and Donald E. Garlikov (Filed With SEC on May 25, 2023)
- First Amendment to Security Agreement dated as of April 25, 2023 between Navidea Biopharmaceuticals, Inc. and John Kim Scott, Jr (Filed With SEC on April 28, 2023)
- Secured Bridge Note dated as of April 25, 2023 (Filed With SEC on April 28, 2023)
- Registration Rights Agreement dated as of April 26, 2023 between Navidea Biopharmaceuticals, Inc. and Keystone Capital Partners, LLC (Filed With SEC on April 28, 2023)
- Common Stock Purchase Agreement dated as of April 26, 2023 between Navidea Biopharmaceuticals, Inc. and Keystone Capital Partners, LLC (Filed With SEC on April 28, 2023)
- Asset Purchase Agreement dated as of April 10, 2023 between Navidea Biopharmaceuticals, Inc. and Meilleur Technologies, Inc (Filed With SEC on April 13, 2023)
- First Amendment to Section 382 Rights Agreement dated as of January 10, 2023 between Navidea Biopharmaceuticals, Inc. and Continental Stock Transfer & Trust Company, LLC (Filed With SEC on January 10, 2023)
- Form of Subscription Rights Certificate (Filed With SEC on August 2, 2022)
- Form of Warrant Agency Agreement between Navidea Biopharmaceuticals, Inc. and Continental Stock Transfer & Trust Company, LLC (Filed With SEC on August 2, 2022)
- Form of Common Stock Purchase Warrant to be issued in rights offering (Filed With SEC on August 2, 2022)
- Certificate of Designations, Preferences and Rights of Series I Convertible Preferred Stock (Filed With SEC on August 2, 2022)
- Form of Subscription Rights Certificate (Filed With SEC on July 20, 2022)
- Form of Warrant Agency Agreement between Navidea Biopharmaceuticals, Inc. and Continental Stock Transfer & Trust Company, LLC (Filed With SEC on July 20, 2022)
- Form of Common Stock Purchase Warrant to be issued in rights offering (Filed With SEC on July 20, 2022)
- Certificate of Designations, Preferences and Rights of Series I Convertible Preferred Stock (Filed With SEC on July 20, 2022)
- Registration Rights Agreement effective as of April 10, 2022 by and between Navidea Biopharmaceuticals, Inc. and John K. Scott, Jr (Filed With SEC on April 12, 2022)
- Security Agreement dated as of April 10, 2022 by Navidea Biopharmaceuticals, Inc. in favor of John Kim Scott, Jr (Filed With SEC on April 12, 2022)
- Secured Term Note, dated April 10, 2022 (Filed With SEC on April 12, 2022)
- Stock Exchange and Loan Agreement between Investor and Navidea Biopharmaceuticals, Inc., dated April 10, 2022 (Filed With SEC on April 12, 2022)
- Section 382 Rights Agreement, dated as of April 7, 2022, between Navidea Biopharmaceuticals, Inc. and Continental Stock Transfer & Trust Company, LLC, as Rights Agent (Filed With SEC on April 12, 2022)
- Amendment to Stock Purchase Agreement and Letter of Investment Intent by and between the Company and Investor dated July 8, 2021 (Filed With SEC on July 13, 2021)
- Registration Rights Agreement by and between the Company and Investor dated March 2, 2021 (Filed With SEC on March 4, 2021)
- Stock Purchase Agreement and Letter of Investment Intent by and between the Company and Investor dated March 2, 2021 (Filed With SEC on March 4, 2021)
- Form of Common Stock Purchase Agreement (Filed With SEC on September 2, 2020)
- Stock Purchase Agreement and Letter of Investment Intent, by and between the Company and Keystone (Filed With SEC on September 2, 2020)
- Stock Purchase Agreement, effective August 9, 2020, by and between Navidea Biopharmaceuticals, Inc. and Jubilant Radiopharma (Filed With SEC on August 12, 2020)
- Stock Purchase Agreement and Letter of Investment Intent by and between the Company and the Investor (Filed With SEC on May 12, 2020)
- Stock Purchase Agreement, effective February 14, 2020, by and between Navidea Biopharmaceuticals, Inc. and John K. Scott (Filed With SEC on March 18, 2020)
- Stock Purchase Agreement, effective February 14, 2020, by and between Navidea Biopharmaceuticals, Inc. and Keystone Capital Partners, LLC (Filed With SEC on March 18, 2020)
- Stock Purchase Agreement, dated December 6, 2019, among Navidea Biopharmaceuticals, Inc. and the purchasers named therein (Filed With SEC on December 11, 2019)
- Registration Rights Agreement, dated December 6, 2019, among Navidea Biopharmaceuticals, Inc. and the stockholders named therein (Filed With SEC on December 11, 2019)
- Underwriting Agreement, dated June 13, 2019, by and between Navidea Biopharmaceuticals, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on June 17, 2019)
- Stock Purchase Agreement, dated March 22, 2019, between Navidea Biopharmaceuticals, Inc. and John K. Scott, Jr (Filed With SEC on May 9, 2019)
